TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05612607

Intervention type: DRUG
Group type: OTHER
Intervention: Immunoglobulin replacement therapy (IGRT)
Description: IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
Study: NCT06279403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Nephrectomy
Description: Radical Nephrectomy: Complete resection of the tumor and affected kidney within the renal fascia.~Partial Nephrectomy: Complete resection of the tumor while preserving maximal kidney function.~Lymph Node Dissection: For patients with evident enlargement of retroperitoneal lymph nodes preoperatively, perform lymph node dissection at the renal hilum, along the ipsilateral major vessels, and anterior to the ipsilateral major vessels. Lymph node dissection is not required for patients without evident enlargement of retroperitoneal lymph nodes preoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.
Study: NCT04892446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered either SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered either SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered IV
Study: NCT05358886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPN14770/ zatolmilast
Description: 25mg BID BPN14770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05839626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445514
Description: Powder for solution for injection. Sub Cutaneous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445514
Description: Powder for solution for injection. Sub Cutaneous administration.
Study: NCT05995418

Intervention type: OTHER
Intervention: There was no intervention as this was an observational study.
Description: There was no intervention as this was an observational study.

Intervention type: OTHER
Intervention: There was no intervention as this was an observational study.
Description: There was no intervention as this was an observational study.

Intervention type: OTHER
Intervention: There was no intervention as this was an observational study.
Description: There was no intervention as this was an observational study.
Study: NCT04918797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIN
Description: Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)
Study: NCT06132750

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05695482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training exercises
Description: The 6-week exercise intervention consists of 25-minute group sessions of Neuromuscular training supervised by a researcher.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip abductors muscular strength exercises
Description: The 6-week exercise intervention consists of of 20-minute group sessions of progressive resistance training, supervised by a researcher.
Study: NCT06535321

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vibration training
Description: After modelling, when the vibration platform is closed, all participants of the control group completed the same action as vibration training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration training
Description: For the vibration group, vibration training was performed immediately after DOMS modelling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration training
Description: For the vibration group, vibration training was performed immediately after DOMS modelling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Y-shaped kinesio taping
Description: For the kinesio group, Y-shaped kinesio taping was performed 30 min before DOMS modelling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Y-shaped kinesio taping
Description: For the kinesio group, Y-shaped kinesio taping was performed 30 min before DOMS modelling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined vibration training and Y-shaped kinesio taping
Description: For the combined group, the vibration group and kinesio group interventions were performed simultaneously.
Study: NCT05343429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzydamine hydrochloride
Description: In BN group,15 ml of 0.15 % Benzydamine hydrochloride (BN) will be dissolved in 15 ml plain water in a sterile container and given to participants before anesthesia for surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: In group AP, Aspirin (AP) 600 mg Aspirin tablets dissolved in 30 ml of plain water in a sterile container will be given to participants for gargling before anesthesia for surgery
Study: NCT05182892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change of stimulation amplitudes in dopaminergic OFF drug state
Description: Change of stimulation amplitudes during experiment in dopaminergic OFF drug state.
Study: NCT05860530

Intervention type: DRUG
Group type: OTHER
Intervention: The test olaparib tablet (T)
Description: The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: The test olaparib tablet (T)
Description: The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: The reference olaparib tablet (R)
Description: The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: The reference olaparib tablet (R)
Description: The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours
Study: NCT05839626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445514
Description: Powder for solution for injection. Sub Cutaneous administration.
Study: NCT05238103

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Corrie Hybrid Cardiac Rehabilitation Program
Description: The Corrie Hybrid Cardiac Rehabilitation Program is a multi-component intervention. It consists of the Corrie smartphone app for cardiovascular health optimization which is paired with wristband device (Apple Watch or Fitbit), Bluetooth-enabled Omron blood pressure monitor and exercise resistance bands. The program also includes individualized treatment plan development, setting health goals and communication with trained Corrie Health Coach. Furthermore, the intervention includes motivational text messages sent to participants throughout the study to aid with risk factor modification.
Study: NCT06549114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leniolisib
Description: The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).
Study: NCT05882903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Dipropionate Nasal Cream 0.0644%
Description: Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe and applicator device
Description: Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
Study: NCT06185530

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Detection of obstructive coronary disease
Description: Detection of obstructive coronary disease

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of obstructive coronary disease
Description: Detection of obstructive coronary disease
Study: NCT06119412

Intervention type: OTHER
Group type: OTHER
Intervention: blood pressure measurement starting with standard technique or alternative new technique. manual sphygmomanometer will be used.
Description: Each participant will have their blood pressure measured with two different techniques.

Intervention type: OTHER
Group type: OTHER
Intervention: blood pressure measurement starting with standard technique or alternative new technique. manual sphygmomanometer will be used.
Description: Each participant will have their blood pressure measured with two different techniques.
Study: NCT06218433

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urothelial cancer screening using urine tumor DNA test
Description: Urine sample DNA is analyzed using a targeted sequencing panel encompassing the coding regions of 21 genes that are recurrently mutated in urothelial cancer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urothelial cancer screening using urine cytology (comparator)
Description: Urine cytology sample
Study: NCT05199272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 23ME-00610
Description: 23ME-00610 given by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 23ME-00610
Description: 23ME-00610 given by IV infusion
Study: NCT05035693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOVE®-C
Description: Momo- or bisegmental implantation of MOVE®-C cervical prothesis.
Study: NCT06149013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindAhead Active
Description: MindAhead's Active app focuses on increasing meaningful and enjoyable cognitive, physical, and social activities specifically adapted to patients with early cognitive decline (MCI or mild dementia). These techniques include psychoeducation (explaining the rationale, the components of behavioral activation, and protective activities), action planning (selecting activities, goal setting, activity scheduling, graded task assignment, written schedules, and step-by-step sequencing) and action/self-monitoring (assessing execution of and enjoyment in activities, monitor mood and cognitive problems), as well as value-based activation (understanding most important values, selecting activities according to these values). This process aims to enable the users to understand which activities are enjoyable and meaningful to them and how to implement these activities into their daily lives. MindAhead's Active app consists of one to five sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual
Description: Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.
Study: NCT04664088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
Study: NCT05266950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)
Description: Recommended lymphodepletion regimen: cyclophosphamide (250 mg/m2/d, ×3d) and fludarabine (30 mg/m2/d, ×3d). If the patient has a hematological toxicity of grade 3 or higher, the alternative regimen is: cyclophosphamide (125mg/m2/d, ×3d) and fludarabine (15 mg/m2/d, ×3d). During lymphodepletion, physicians can give anti-myeloid drugs such as demethoxydaunorubicin or daunorubicin as appropriate.
Study: NCT05528133

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Genomically Guided Radiation Therapy
Description: Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
Study: NCT05629637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Resilience Training (MBRT)
Description: MBRT is designed to enhance resilience in the presence of acute and chronic LEO stressors. MBRT will be delivered in a hybrid format. An intensive, 22-hour in-person training will be offered, followed by 4 weekly 90-minute zoom classes. The in-person portion of the training will span 3 days: 4 hours day 1, 6 hours day 2, and 6 hours day 3. MBRT contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions. MBRT is designed to address stressors inherent to police work, including critical incidents, job dissatisfaction, public scrutiny, and interpersonal, affective and behavioral challenges.
Study: NCT06147921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verasone
Description: Administered by sinonasal irrigation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verasone
Description: Administered by sinonasal irrigation.
Study: NCT06519877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber
Description: Soluble corn fiber, also referred to resistant maltodextrin, is a type of dietary fiber made from corn starch. Soluble corn fiber is typically used to thicken processed foods and has been marketed as a prebiotic to improve digestive health.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber
Description: Soluble corn fiber, also referred to resistant maltodextrin, is a type of dietary fiber made from corn starch. Soluble corn fiber is typically used to thicken processed foods and has been marketed as a prebiotic to improve digestive health.
Study: NCT06218589

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Velacur
Description: Velacur is a liver ultrasound that measures hepatic fat and fibrosis through the propagation of a continuously, externally conducted shear wave. An enrolled participant may choose to do the ultrasound at the time of a clinic visit, or research visit or a scheduled radiology visit according to manufacturer's instructions by trained study staff. Fibrosis and steatosis measures will be collected from all scans.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants who have not had an MRI within the past two years will be offered a research MRI (no contrast or sedation will be used) to measure hepatic fat and hepatic stiffness (if required). Participants who have had an MRI or liver biopsy in the past two years will use historical data comparison data. MRI data will include the PDFF hepatic fat, any assessment of fibrosis and notes of other abnormalities.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample collection for biomarkers
Description: Biomarkers are metabolic thumbprints of how the body is behaving to different health or disease processes, some of the biomarkers can be studied from plasma or serum combined with other demographics. A lipid profile and comprehensive metabolic panel (CMP), if not obtained clinically within 4 weeks, will be collected as a standard of care.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Description: Liver biopsy data will be collected only if liver biopsy is done clinically when available and scored using the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) approach.
Study: NCT06533384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Description: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Description: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Study: NCT06633406

Intervention type: OTHER
Intervention: Age-appropriate Wechsler Intelligence Test
Description: 2.5-6 years: Wechsler Preschool and Primary Scale of Intelligence for children (WPPSI IV)~7-16 years: Wechsler Intelligence Scale for Children (WISC V)~\>17 years: Wechsler Adult Intelligence Scale (WAIS IV)

Intervention type: OTHER
Intervention: Age-appropriate Wechsler Intelligence Test
Description: 2.5-6 years: Wechsler Preschool and Primary Scale of Intelligence for children (WPPSI IV)~7-16 years: Wechsler Intelligence Scale for Children (WISC V)~\>17 years: Wechsler Adult Intelligence Scale (WAIS IV)

Intervention type: OTHER
Intervention: Disruptive Behavior Disorders Rating Scale
Description: Dutch version of the Disruptive Behavior Disorders Rating Scale

Intervention type: OTHER
Intervention: Disruptive Behavior Disorders Rating Scale
Description: Dutch version of the Disruptive Behavior Disorders Rating Scale

Intervention type: OTHER
Intervention: Social Responsiveness Scale
Description: 3-18 years: social responsiveness scale 2 (SRS-2)~\>19 years: Social Responsiveness Scale - Adult version (SRS-A)

Intervention type: OTHER
Intervention: Social Responsiveness Scale
Description: 3-18 years: social responsiveness scale 2 (SRS-2)~\>19 years: Social Responsiveness Scale - Adult version (SRS-A)
Study: NCT05828823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis twice weekly
Description: Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis thrice weekly
Description: Conventional hemodialysis regimen
Study: NCT04718675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB-0742
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB-0742
Description: Oral capsules
Study: NCT05783219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: 4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
Study: NCT06533384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9 cycles of Camrelizumab as adjuvant therapy.
Description: 9 cycles of Camrelizumab as adjuvant therapy.
Study: NCT06147921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verasone
Description: Administered by sinonasal irrigation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verasone
Description: Administered by sinonasal irrigation.
Study: NCT00888082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 mg depot injectable preparation
Study: NCT06450704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Daily walking. Participants will be given an activity band to self-monitor the number of steps they walk each day during the 12-week intervention period. Each participant must reach a certain number of daily steps with a progressive goal adjusted to the number of steps from the previous week. The goal is set considering the superior number to the median of steps of the preceding week.~Weekly combined exercise sessions (aerobic + strength exercise) 2 sessions of 60 minutes per week in a 12-week program. The exercise intervention will combine the use of elastic bands and the body weight. First, 5 minutes of warm-up; second, training circuit with low-intensity strength exercises alternating work and rest times using rhythmic music. Upper, lower and middle body exercises will alternate. The program will progress in intensity, work: rest ratio, and technical difficulty of the exercises. At the end of the main part, there will be a cool-down and stretching for 5 minutes.
Study: NCT06355687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Supplement
Description: Obese patients undergoing laparoscopic cholecystectomy will receive placebo medication (Vitamin Supplement) 45 minutes before general anesthesia.